en
Scientific article
Open access
English

Detectable Vesicular Stomatitis Virus (VSV)-specific humoral and cellular immune responses following VSV-Ebola virus vaccination in humans

Published inThe Journal of Infectious Diseases, vol. 219, no. 4, p. 556-561
Publication date2019
Abstract

In response to the Ebola virus (EBOV) crisis of 2013-2016, a recombinant vesicular stomatitis virus (VSV)-based EBOV vaccine was clinically tested (NCT02283099). A single-dose regimen of VSV-EBOV revealed a safe and immunogenic profile and demonstrated clinical efficacy. While EBOV-specific immune responses to this candidate vaccine have previously been investigated, limited human data on immunity to the VSV vector are available. Within the scope of a phase 1 study, we performed a comprehensive longitudinal analysis of adaptive immune responses to internal VSV proteins following VSV-EBOV immunization. While no preexisting immunity to the vector was observed, more than one-third of subjects developed VSV-specific cytotoxic T-lymphocyte responses and antibodies.

Keywords
  • Adult
  • Antibody Formation
  • Ebola Vaccines/administration & dosage/immunology
  • Humans
  • Immunity
  • Cellular
  • Longitudinal Studies
  • Vaccines
  • Synthetic/administration & dosage/immunology
  • Vesiculovirus/immunology
Citation (ISO format)
POETSCH, Joseph H et al. Detectable Vesicular Stomatitis Virus (VSV)-specific humoral and cellular immune responses following VSV-Ebola virus vaccination in humans. In: The Journal of Infectious Diseases, 2019, vol. 219, n° 4, p. 556–561. doi: 10.1093/infdis/jiy565
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal0022-1899
139views
97downloads

Technical informations

Creation10/15/2020 2:19:00 PM
First validation10/15/2020 2:19:00 PM
Update time03/15/2023 11:35:43 PM
Status update03/15/2023 11:35:41 PM
Last indexation02/12/2024 11:59:15 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack